Chronic Bronchitis
Conditions
Brief summary
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis.
Detailed description
The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. Two sessions of treatment will be delivered one month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session (approximately one month after the right side is treated). Treatment will be delivered by a respiratory physician (interventional pulmonologist) in a tertiary teaching hospital during a bronchoscopic procedure. The bronchoscopy will be delivered during general anaesthesia. It is anticipated that the bronchoscopic procedure will last less than 60 minutes in total. Treatment will be deemed to have been delivered following the successful treatment during the two bronchoscopies. A third bronchoscopy will be performed three months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
Interventions
The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
Sponsors
Gala Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Intervention model description
Treatment with Gala Airway Treatment System (RheOx)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject is diagnosed with chronic bronchitis for a minimum of two years, where chronic bronchitis is defined clinically as chronic productive cough for three months in each of two successive years in a patient in whom other causes of productive cough have been excluded. 2. Subject's responses to the first two questions of the CAT must sum to at least 7 points. 3. Subject has GOLD Stage II chronic obstructive pulmonary disease (COPD) with a preprocedure post-bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within three months of enrollment. Subjects with a preserved function (FEV1 \> 80%) are allowed if the subject has a total CAT score greater than or equal to 10 and the sum of the first two questions of the CAT score sum to at least 7 points. 4. Subject has a cigarette smoking history of at least ten packs years. 5. Subject in the opinion of the site investigator is able to adhere to and undergo three bronchoscope procedures inclusive of lung biopsies and Gala treatments and has provided a signed informed consent.
Exclusion criteria
1. Subject has active respiratory infection (e.g., common cold, pneumonia, MAI, tuberculosis) or COPD exacerbation within the last 6 wees prior to study treatment bronchscopy. 2. Subject is treated with \> 10 mg of prednisolone or prednisone per day. 3. Subject has an implantable cardioverter defibrillator or pacemaker. 4. Subject has a history of cardiac arrhythmia within past two years. 5. Subject has abnormal cardiac rhythm at time of procedure. 6. Subject has history of proven lung cancer in last 5 years. 7. Subject has pulmonary nodule or cavity requiring follow-up or intervention unless proven benign and not actively infected (e.g., aspergilloma). 8. Subject has prior lung surgery, such as lung transplant, LVRS, lung implant/prosthesis, metal stent, valves, coils, bullectomy, segmentectomy, or lobectomy. Pneumothorax without lung resection is acceptable. Pleural procedures without surgery are acceptable. 9. Subject has Alpha-1-Antitrypsin (AAT) deficiency. 10. Subject has documented history of asthma diagnosed with onset \<30 years of age, clinically significant bronchiectasis or any other significant second lung disease. 11. Subject actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 6 months. 12. Subject has the inability to walk over 140 meters. 13. Subject has a serious medical condition, such as: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, hypertension, autoimmune disease or uncontrolled gastric reflux. 14. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines). 15. Subject is pregnant, nursing, or planning to get pregnant during study duration. 16. Subject has received chemotherapy within the past 6 months or is expected to receive chemotherapy during participation in this study. 17. Subject is or has been in another clinical investigational study within 6 weeks of baseline. 18. Subject on anticoagulation for cardiovascular indications and is unable to have anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for at least seven days prior to bronchoscopy in the opinion of the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Incidence and evaluation of any serious adverse events associated with the Gala Airway Treatment System through 6 months. | 6 months | Incidence and evaluation of any serious adverse events associated with the Gala Airway Treatment System through 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Utility - Histology | 3 months following bilateral treatment | Histopathological evidence of change in mucus producing cells within the airway. |
| Clinical Utility - Pulmonary Function | Through end of study (12-months post-bilateral treatment) | Pulmonary function testing (PFT) utilizing Forced Expiratory Volume (FEV1) |
| Quality of Life - COPD Assessment Test (CAT) | Through end of study (12-months post-bilateral treatment) | COPD Assessment Test (CAT) questionnaire |
| Acute Exacerbations | From 48 hours post procedure through end of study (12 months post-bilateral treatment) | Detection of acute exacerbations (measured by clinical examination of a suitably qualified physician) |
| Non-Acute Exacerbations | From 48 hours post procedure through end of study (12 months post-bilateral treatment) | Detection of non-acute exacerbations (measured by clinical examination of a suitably qualified physician) |
| Six Minute Walk Test (6MWT) | 6 months post-bilateral treatment | Change in 6MWT at 6 months compared to baseline |
| Quality of Life - SGRQ | Through end of study (12-months post-bilateral treatment) | Patient filled respiratory questionnaire: St. George Respiratory Questionnaire (SGRQ) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cough and Sputum Assessment Questionnaire (CASA-Q) | Through end of study (12-months post-bilateral treatment) | Patient reported outcome respiratory questionnaire: Cough and Sputum Assessment |
Countries
Austria, Chile
Outcome results
None listed